The bank, in a report, recalls the losses that the pharmaceutical Gilead has had after healing hepatitis C.
Goldman Sachs has a advice for biotechnology companies: healing patients can stop their business dry.In fact, American bank analysts throw a direct question."Is patient healing a sustainable commercial model?"In this way, experts have been directed in a April 10 report entitled "The Genome Revolution" where market problems are addressed.
The question is not raised because yes.The last movements of the sector serve as an example to Goldman Sachs to warn of the risks.In his report, analyst Salveen Richter has not overlooked the recent trajectory of Gilead Sciences, the pharmaceutical treatment for hepatitis C. multinational sales in the US reached a maximum of 12.5 billion dollars in 2015 ... but sincePatients have begun to be cured, the company's sales have been chopped, as well as that Wall Street's blows have appeared.
En 1922 descubrieron la insulina, en 1930 la insulina lenta. ¿Que c*** han hecho desde entonces?
There is no more solution than public research.And sink the pharmacists who do not heal. The one found by the cure of hepatitis C, should be favored to the maximum in sales
Hija de 35 años , diabética desde los 5. Glico: normalmente de 6 , pero 6,7 la última ( 6,2 marcaba el Free) Fiasp: 4- 4- 3 Toujeo: 20
@"Regina" In this world, what matters is money, diabetes surely has a cure for years but of course a cure does not interest, diabetes gives many tickets and that is what matters, it is sad but it is so, it is so,The same happened with an Italian doctor who discovered the cure of cancer with sodium bicarbonate, and was threatened with death by the pharmaceuticalThey send to kill for investigating priests, in short this is this world.
@"Sefoz97" Do not compare, the Italian is chemically pure conspiracy.If Tarch wants to kill him, they will be the relatives of the people who have "cured" with bicarbonate. And I believe it perfectly, the pharmaceutical industry does not investigate to cure chronic diseases but to earn money.That research, basic for nosostros, should be in the hands of the public university, which waste huge amounts of money in isolated research and that do not contribute much.And on top of that, when they get something promising, the researchers leave with the patent to the private industry.Puaj!.
